Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
{{output}}
Background: Ripretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation. This study analy... ...
